Author: Aviles, Agustin

Source: Reviews on Recent Clinical Trials, Volume 4, Number 2, May 2009 , pp. 131-139(9)

Publisher: Bentham Science Publishers

Abstract:

Management of hematological malignancies (HM) during pregnancy remains unsolved. Presence of adverse events in mother and child: spontaneous abortion, stillborn, premature, low-weight and congenital abnormalities have been attributed to the use of chemotherapy, especially during first trimester. We reviewed the English and Spanish literature of reports which documented the use of chemotherapy for HM during pregnancy, in order to evaluate the association of adverse events in mother and the fetus. We reviewed 1395 cases of this association, although adverse events was more frequent that did not complicate pregnancy, other causes such as concomitant illness or maternal complications and use of other potentially toxic drugs during pregnancy had not been considered. No clear differences was observed if chemotherapy were administered during 1° or 2° and 3° trimester of pregnancy. Longer follow-up was not available in most reports. We cannot confirm the presence of late toxicity secondary to chemotherapy and radiotherapy, because data are not available. We conclude that the use of chemotherapy can be safely administered during 2° and 3° trimester. Taking into consideration the dates of these brief reports no appear that the use of chemotherapy during first trimester could be dangerous to mother and fetus. It is necessary to consolidate all dates of this association to come to definitive conclusions.

Keywords: Acute leukemia; pregnancy; lymphoma; Hodgkin lymphoma; doxorubicin

Document Type: Research article

Publication date: 2009-05-01

More about this publication?

• Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I - IV clinical trial studies, clinical investigations at all stages of development and therapeutics.
  
  The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Aviles, Agustin

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers